We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

76 hedge funds and large institutions have $365M invested in Celldex Therapeutics in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,008% more capital invested

Capital invested by funds: $7.15M → $365M (+$358M)

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

388% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 8

185% more call options, than puts

Call options by funds: $13.2M | Put options by funds: $4.61M

69% more funds holding

Funds holding: 45 → 76 (+31)

54.61% more ownership

Funds ownership: 22.58% → 77.19% (+55%)

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

Holders
76
Holders Change
+31
Holders Change %
+68.89%
% of All Funds
1.56%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.1%
New
39
Increased
12
Reduced
10
Closed
8
Calls
$13.2M
Puts
$4.61M
Net Calls
+$8.55M
Net Calls Change
+$8.38M

Top Buyers

1
BI
BVF Inc
California
+$12.1M
2
RI
RTW Investments
New York
+$11.6M
3
LGM
Logos Global Management
California
+$8.86M
4
RG
Redmile Group
California
+$8.86M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$7.76M

Top Sellers

1
MG
Meditor Group
Bermuda
-$993K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$313K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$174K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$85.5K
5
BCM
Bridgeway Capital Management
Texas
-$83K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$35.6M +$12.1M +2,740,000 New
RI
2
RTW Investments
New York
$33.9M +$11.6M +2,610,000 New
LGM
3
Logos Global Management
California
$26M +$8.86M +2,000,000 New
RG
4
Redmile Group
California
$26M +$8.86M +2,000,000 New
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$22.8M +$7.76M +1,750,000 New
IC
6
Ikarian Capital
Texas
$21.4M +$7.3M +1,647,439 New
Renaissance Technologies
7
Renaissance Technologies
New York
$21.3M +$2.07M +466,988 +40%
VC
8
Vivo Capital
California
$20.8M +$7.09M +1,600,000 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$16.9M +$3.36M +758,278 +141%
RCM
10
RA Capital Management
Massachusetts
$14.9M +$5.1M +1,150,000 New
OM
11
Opaleye Management
Massachusetts
$13.9M +$4.75M +1,071,000 New
ACP
12
Acuta Capital Partners
California
$13M +$4.43M +1,000,000 New
BC
13
Boxer Capital
California
$13M +$4.43M +1,000,000 New
EP
14
Eversept Partners
New York
$9.27M +$3.16M +712,698 New
O
15
OrbiMed
New York
$8.13M +$2.77M +625,000 New
EAM
16
Eventide Asset Management
Massachusetts
$6.02M +$2.05M +463,335 New
CA
17
Corriente Advisors
Texas
$5.98M +$2.04M +460,000 New
CAM
18
Cresset Asset Management
Illinois
$5.95M – – –
Millennium Management
19
Millennium Management
New York
$5.6M +$1.91M +430,564 New
BlackRock
20
BlackRock
New York
$5.36M +$301K +67,969 +20%
TCMG
21
TSP Capital Management Group
New Jersey
$4.78M – – –
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$3.99M -$174K -39,193 -11%
MIM
23
Monashee Investment Management
Massachusetts
$3.9M +$1.33M +300,000 New
PVI
24
Pura Vida Investments
New York
$3.25M +$1.11M +250,100 New
Acadian Asset Management
25
Acadian Asset Management
Massachusetts
$2.96M -$313K -70,634 -24%
1
2 3 4

CLDX Hedge Fund Activity: Q2 2020 in Review

76 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2020, worth a combined $365M — up 5,008% from $7.15M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CLDX positions and 8 closed out — a net gain of 31 holders — while 12 added to existing stakes and 10 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $12.1M. The largest seller was Meditor Group, cutting an estimated $993K.

  • 76 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2020, up from 45 in Q1 2020.
  • Funds reported $365M of Celldex Therapeutics stock for Q2 2020, up 5,008% quarter-over-quarter.
  • 39 funds opened new Celldex Therapeutics positions in Q2 2020 and 8 closed out, a net change of +31 holders.
  • The largest Celldex Therapeutics buyer in Q2 2020 was BVF Inc, an estimated $12.1M added.
  • The largest Celldex Therapeutics seller in Q2 2020 was Meditor Group, an estimated $993K sold.

Based on aggregated 13F filings for Q2 2020.